EA200200802A1 - 5-ALKYLPYRIDO [2.3-d] Pyrimidine Thyrosine Kinase Inhibitors - Google Patents
5-ALKYLPYRIDO [2.3-d] Pyrimidine Thyrosine Kinase InhibitorsInfo
- Publication number
- EA200200802A1 EA200200802A1 EA200200802A EA200200802A EA200200802A1 EA 200200802 A1 EA200200802 A1 EA 200200802A1 EA 200200802 A EA200200802 A EA 200200802A EA 200200802 A EA200200802 A EA 200200802A EA 200200802 A1 EA200200802 A1 EA 200200802A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sor
- cor
- compounds
- hydrogen
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Описаны соединения формулы I, где Rпредставляет собой водород, алкил или циклоалкил; Rпредставляет собой водород, низший алкил, низшую алкоксигруппу, галоген, трифторметил, низший алкинил, низший алкенил, нитрил, нитрогруппу, -COR, -COR, -CONRR, -CONROR, -SONRR, -SOR, -SOR, (формулу (II)) или -NRR; Y представляет собой N или CR; Rпредставляет собой низший алкил, галогеналкил или арил; Х и Z независимо представляют собой водород, галоген, низший алкил, низшую алкоксигруппу, трифторметил, гидроксигруппу, нитрил, нитрогруппу, -NRR, -N(O)RR, -NRRRW, -SR, -C(O)R, -COR, -CONRR, -SONRR, -SOR, -SOR, P(O)(OR)(OR), -T(CH)QR, -C(O)T(CH)QRили -NRC(O)T(CH)QR; m является числом от 1 до 6. Эти соединения можно применять для лечения пролиферативных заболеваний клеток, таких как рак, атеросклероз и повторный стеноз. Эти соединения являются сильными ингибиторами циклинзависимых киназ (cdks) и киназ, опосредованных фактором роста.Международная заявка была опубликована вместе с отчетом о международном поиске.Compounds of formula I are described, wherein R <1> is hydrogen, alkyl or cycloalkyl; R1 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR, -COR, -CONRR, -CONROR, -SONRR, -SOR, -SOR, (formula (II) ) or -NRR; Y is N or CR; R4 is lower alkyl, haloalkyl or aryl; X and Z independently represent hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NRR, -N (O) RR, -NRRRW, -SR, -C (O) R, -COR, -CONRR, -SONRR, -SOR, -SOR, P (O) (OR) (OR), -T (CH) QR, -C (O) T (CH) QR or -NRC (O) T (CH) QR ; m is a number from 1 to 6. These compounds can be used to treat cell proliferative diseases, such as cancer, atherosclerosis, and re-stenosis. These compounds are strong inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The international application was published along with an international search report.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18712400P | 2000-03-06 | 2000-03-06 | |
PCT/US2001/002657 WO2001070741A1 (en) | 2000-03-06 | 2001-01-29 | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200200802A1 true EA200200802A1 (en) | 2003-02-27 |
Family
ID=22687699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200200802A EA200200802A1 (en) | 2000-03-06 | 2001-01-29 | 5-ALKYLPYRIDO [2.3-d] Pyrimidine Thyrosine Kinase Inhibitors |
Country Status (36)
Country | Link |
---|---|
EP (1) | EP1268476A1 (en) |
JP (1) | JP2003528101A (en) |
KR (1) | KR20020075805A (en) |
CN (1) | CN1422268A (en) |
AP (1) | AP2002002643A0 (en) |
AR (1) | AR034119A1 (en) |
AU (1) | AU2001233028A1 (en) |
BG (1) | BG107161A (en) |
BR (1) | BR0109056A (en) |
CA (1) | CA2401368A1 (en) |
CO (1) | CO5280200A1 (en) |
CR (1) | CR6736A (en) |
CZ (1) | CZ20022929A3 (en) |
DZ (1) | DZ3308A1 (en) |
EA (1) | EA200200802A1 (en) |
EE (1) | EE200200506A (en) |
GT (1) | GT200100037A (en) |
HN (1) | HN2001000040A (en) |
HR (1) | HRP20020798A2 (en) |
HU (1) | HUP0300136A2 (en) |
IL (1) | IL151480A0 (en) |
IS (1) | IS6524A (en) |
MA (1) | MA26881A1 (en) |
MX (1) | MXPA02008535A (en) |
NO (1) | NO20024235L (en) |
NZ (1) | NZ520962A (en) |
OA (1) | OA12227A (en) |
PA (1) | PA8513201A1 (en) |
PE (1) | PE20011177A1 (en) |
PL (1) | PL358271A1 (en) |
SK (1) | SK12472002A3 (en) |
SV (1) | SV2001000338A (en) |
TN (1) | TNSN01036A1 (en) |
WO (1) | WO2001070741A1 (en) |
YU (1) | YU66502A (en) |
ZA (1) | ZA200207110B (en) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
CZ20031125A3 (en) | 2000-10-23 | 2003-10-15 | Smithkline Beecham Corporation | Novel compounds |
NZ526961A (en) * | 2001-02-12 | 2005-03-24 | F | 6-substituted pyrido-pyrimidines |
EP1364950A4 (en) * | 2001-02-26 | 2005-03-09 | Tanabe Seiyaku Co | Pyridopyrimidine or naphthyridine derivative |
US20030100572A1 (en) * | 2001-06-21 | 2003-05-29 | Ariad Pharmaceuticals,Inc. | Novel pyridopyrimidones and uses thereof |
US20030105115A1 (en) * | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
EA007395B3 (en) * | 2002-01-22 | 2018-02-28 | Уорнер-Ламберт Компани Ллс | 2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
PL373339A1 (en) | 2002-04-19 | 2005-08-22 | Smithkline Beecham Corporation | Novel compounds |
CA2494061C (en) | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
ATE380810T1 (en) | 2002-10-09 | 2007-12-15 | Critical Outcome Technologies | PROTEIN TYROSINE KINASE INHIBITORS |
WO2004065378A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
WO2005047284A1 (en) | 2003-11-13 | 2005-05-26 | F. Hoffmann-La Roche Ag | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
DE102004029784A1 (en) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments |
DE102004033670A1 (en) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New pyridodihydropyrazinone, process for its preparation and its use as a medicament |
FR2873118B1 (en) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
EP1630163A1 (en) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinones, methods for their preparation and their use as drugs |
CA2575804A1 (en) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinones used as plk (polo like kinase) inhibitors |
DE102004058337A1 (en) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of fused piperazin-2-one derivatives |
AU2006204724A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
EP1868612A4 (en) | 2005-03-25 | 2010-03-24 | Glaxo Group Ltd | Novel compounds |
UY29440A1 (en) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | NEW COMPOUNDS |
MX2007012951A (en) | 2005-03-25 | 2008-01-11 | Glaxo Group Ltd | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives. |
PE20061193A1 (en) | 2005-03-25 | 2006-12-02 | Glaxo Group Ltd | DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38 |
US7737155B2 (en) * | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
FR2887882B1 (en) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
TW200800983A (en) | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
US7642270B2 (en) | 2005-09-14 | 2010-01-05 | Janssen Pharmaceutica N.V. | 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase |
EA016945B1 (en) * | 2005-10-07 | 2012-08-30 | Экселиксис, Инк. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
CA2624965A1 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k.alpha. |
FR2896246B1 (en) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
ES2366489T3 (en) | 2006-09-15 | 2011-10-20 | Pfizer Products Inc. | PIRID COMPOUND (2,3-D) PIRIDINONE AND ITS USE AS PI3 INHIBITORS. |
BRPI0715566A2 (en) * | 2006-10-16 | 2013-07-02 | Gpc Biotech Inc | compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound |
EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
US20080114007A1 (en) * | 2006-10-31 | 2008-05-15 | Player Mark R | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
FR2910813B1 (en) | 2006-12-28 | 2009-02-06 | Sanofi Aventis Sa | NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA |
BRPI0809998B8 (en) * | 2007-04-03 | 2021-05-25 | Array Biopharma Inc | imidazo[1,2-a]pyridine compound as receptor tyrosine kinase inhibitors, their uses, their preparation processes and pharmaceutical compositions |
JP5129812B2 (en) | 2007-06-15 | 2013-01-30 | Msd株式会社 | Bicycloaniline derivatives |
WO2009019205A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
CN101945867A (en) | 2007-12-19 | 2011-01-12 | 安姆根有限公司 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
WO2009079797A1 (en) | 2007-12-26 | 2009-07-02 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
EP2100894A1 (en) * | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
EP2278973B1 (en) | 2008-04-07 | 2011-11-02 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
EP3023426A1 (en) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
UY32153A (en) | 2008-09-30 | 2011-04-29 | Exelixis Inc | PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
JP2013507395A (en) * | 2009-10-09 | 2013-03-04 | アフラクシス・インコーポレイテッド | 8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidin-7 (8H) -one for the treatment of CNS disorders |
CA2784749C (en) | 2009-12-18 | 2017-12-12 | E. Premkumar Reddy | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
US8901137B2 (en) | 2010-02-09 | 2014-12-02 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors |
CA2794952C (en) | 2010-04-01 | 2018-05-15 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
NZ606281A (en) | 2010-08-05 | 2014-09-26 | Univ Temple | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
WO2012074951A1 (en) | 2010-11-29 | 2012-06-07 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
ES2543569T3 (en) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Dual condensed tricyclic inhibitors of CDK 4/6 and FLT3 |
CA2836410C (en) * | 2011-05-17 | 2019-08-20 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
MX2014010176A (en) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Pyridopyrimidinone inhibitors of kinases. |
PT2958916T (en) * | 2013-02-21 | 2018-11-21 | Pfizer | Solid forms of a selective cdk4/6 inhibitor |
JP2016525532A (en) | 2013-07-26 | 2016-08-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Treatment of myelodysplastic syndrome |
WO2016015597A1 (en) * | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
TWI646094B (en) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
LT3497103T (en) | 2016-08-15 | 2021-07-26 | Pfizer Inc. | Pyridopyrimdinone cdk2/4/6 inhibitors |
CN110809576B (en) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | FGFR kinase inhibitor and pharmaceutical use |
KR20200131246A (en) | 2018-02-15 | 2020-11-23 | 누베이션 바이오 인크. | Heterocyclic compounds as kinase inhibitors |
CN113166148B (en) * | 2018-12-07 | 2024-04-12 | 杭州英创医药科技有限公司 | Heterocyclic compounds as CDK-HDAC dual pathway inhibitors |
CN112759589B (en) * | 2019-11-01 | 2022-04-08 | 暨南大学 | Pyrimidopyridinones and their use |
US11697648B2 (en) | 2019-11-26 | 2023-07-11 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as JAK inhibitors |
JP2024508901A (en) * | 2021-03-08 | 2024-02-28 | 曁南大学 | Pyridopyrimidine compounds and their uses |
CN117720531A (en) * | 2022-09-16 | 2024-03-19 | 华东师范大学 | Pyridopyrimidine derivatives as RSK inhibitors and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
EP0964864B1 (en) * | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
ES2310039T3 (en) * | 1998-05-26 | 2008-12-16 | Warner-Lambert Company Llc | BICYCLE PYRIMIDINES AND BICYCLE 3,4-DIHYDROPIRIMIDINS AS INHIBITORS OF CELL PROLIFERATION. |
-
2001
- 2001-01-29 SK SK1247-2002A patent/SK12472002A3/en unknown
- 2001-01-29 EA EA200200802A patent/EA200200802A1/en unknown
- 2001-01-29 KR KR1020027011627A patent/KR20020075805A/en not_active Application Discontinuation
- 2001-01-29 HU HU0300136A patent/HUP0300136A2/en unknown
- 2001-01-29 MX MXPA02008535A patent/MXPA02008535A/en not_active Application Discontinuation
- 2001-01-29 DZ DZ013308A patent/DZ3308A1/en active
- 2001-01-29 AU AU2001233028A patent/AU2001233028A1/en not_active Abandoned
- 2001-01-29 JP JP2001568942A patent/JP2003528101A/en not_active Abandoned
- 2001-01-29 PL PL01358271A patent/PL358271A1/en not_active Application Discontinuation
- 2001-01-29 CN CN01807590A patent/CN1422268A/en active Pending
- 2001-01-29 EE EEP200200506A patent/EE200200506A/en unknown
- 2001-01-29 YU YU66502A patent/YU66502A/en unknown
- 2001-01-29 IL IL15148001A patent/IL151480A0/en unknown
- 2001-01-29 CZ CZ20022929A patent/CZ20022929A3/en unknown
- 2001-01-29 WO PCT/US2001/002657 patent/WO2001070741A1/en active IP Right Grant
- 2001-01-29 CA CA002401368A patent/CA2401368A1/en not_active Abandoned
- 2001-01-29 OA OA1200200281A patent/OA12227A/en unknown
- 2001-01-29 EP EP01905114A patent/EP1268476A1/en not_active Withdrawn
- 2001-01-29 NZ NZ520962A patent/NZ520962A/en unknown
- 2001-01-29 BR BR0109056-9A patent/BR0109056A/en not_active IP Right Cessation
- 2001-01-29 AP APAP/P/2002/002643A patent/AP2002002643A0/en unknown
- 2001-03-02 TN TNTNSN01036A patent/TNSN01036A1/en unknown
- 2001-03-05 HN HN2001000040A patent/HN2001000040A/en unknown
- 2001-03-05 AR ARP010101039A patent/AR034119A1/en unknown
- 2001-03-05 SV SV2001000338A patent/SV2001000338A/en not_active Application Discontinuation
- 2001-03-05 PE PE2001000216A patent/PE20011177A1/en not_active Application Discontinuation
- 2001-03-05 GT GT200100037A patent/GT200100037A/en unknown
- 2001-03-05 CO CO01017398A patent/CO5280200A1/en not_active Application Discontinuation
- 2001-03-05 PA PA20018513201A patent/PA8513201A1/en unknown
-
2002
- 2002-08-23 CR CR6736A patent/CR6736A/en not_active Application Discontinuation
- 2002-08-23 IS IS6524A patent/IS6524A/en unknown
- 2002-09-04 MA MA26801A patent/MA26881A1/en unknown
- 2002-09-04 ZA ZA200207110A patent/ZA200207110B/en unknown
- 2002-09-05 NO NO20024235A patent/NO20024235L/en not_active Application Discontinuation
- 2002-10-02 BG BG107161A patent/BG107161A/en unknown
- 2002-10-04 HR HR20020798A patent/HRP20020798A2/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200200802A1 (en) | 5-ALKYLPYRIDO [2.3-d] Pyrimidine Thyrosine Kinase Inhibitors | |
EA200200643A1 (en) | PYRIDO [2,3-d] PYRIMIDIN-2,7-DIAMINE KINAZ INHIBITORS | |
EA200001171A1 (en) | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | |
TW200744604A (en) | P38 MAP kinase inhibitors and methods for using the same | |
GEP20063915B (en) | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS | |
DK1070056T3 (en) | Phthalazinone PDE III / IV Inhibitors | |
PT1294724E (en) | COMPOUNDS PYRROLE (2,3-D) PYRIMIDINE AS IMMUNOSPRESSOR AGENTS | |
ATE461179T1 (en) | ACT ACTIVITY INHIBITOR | |
EA200000969A1 (en) | CGMB PDE5 INHIBITORS ON THE BASIS OF PYRAZOLPIRIMIDINONA FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS | |
CY1111083T1 (en) | Nicotinamide derivatives useful as P38 inhibitors | |
TR200401903T4 (en) | Imidazole-2-carboxamide derivatives as shelf kinase inhibitor. | |
EA200300674A1 (en) | OBTAINING HETEROCYCLIC SULPHONAMIDE INHIBITORS BETA-AMYLOID | |
ATE384723T1 (en) | N,N'-DIPHENYL UREA DERIVATIVES SUITABLE AS KINASE INHIBITORS | |
CO5271675A1 (en) | DECAHIDRO-ISOQUINOLINAS DERIVATIVES, PROCESS FOR THE PREPARATION, COMPOSITION AND PHARMACEUTICAL COMPOUNDS CONTAINING THEM | |
MY143245A (en) | 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases | |
ATE476434T1 (en) | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | |
ATE403653T1 (en) | PYRIDINE-SUBSTITUTED FURAN DERIVATIVES AS RAF-KINASE INHIBITORS | |
EA200400475A1 (en) | SUBSTITUTED DERIVATIVES OF BENZIMIDAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF MALIGNANT TUMOR | |
CO5680420A2 (en) | COMPOUNDS OF 6-AMINO-1H-INDAZOL AND 4-AMINOBENZENOFURAN AS INHIBITORS OF PHOSPHODIESTERASE 4 | |
AR035434A1 (en) | FLUORALCOXIFENILSULFONILUREAS REPLACED, PROCEDURE FOR PREPARATION, PROCEDURE TO COMBAT THE INDESEABLE GROWTH OF PLANTS OR MICROORGANISMS, USE OF THESE COMPOUNDS TO COMBAT THE INDESEABLE GROWTH OF THE PLANTS OR THE MICRO ORGANISTS AND HER | |
PE20020524A1 (en) | 7-OXO-PYRIDOPYRIMIDINES AS KINASE INHIBITORS | |
BRPI0407841A (en) | heterocyclic kinase inhibitors | |
DE602004005881D1 (en) | SUBSTITUTED PYRAZINONE COMPOUNDS FOR THE TREATMENT OF IGNITION | |
ATE296827T1 (en) | HETEROPOLYCYCLIC INHIBITORS | |
ATE333457T1 (en) | CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS |